|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Validation of the Rockall scoring system for outcomes from non-variceal upper gastrointestinal bleeding in a Canadian setting显示文摘AIM: To validate the Rockall scoring system for predicting outcomes of rebleeding, and the need for a surgical procedure and death. METHODS: We used data extracted from the Registry of Upper Gastrointestinal Bleeding and Endoscopy including information of 1869 patients with non-variceal upper gastrointestinal bleeding treated in Canadian hospitals. Risk scores were calculated and used to classify patients based on outcomes. For each outcome, we used χ2 goodness-of-fit tests to assess the degree of calibration, and built receiver operating characteristic curves and calculated the area under the curve (AUC) to evaluate the discriminative ability of the scoring system. RESULTS: For rebleeding, the χ2 goodness-of-fit test indicated an acceptable fit for the model [χ2 (8) = 12.83, P = 0.12]. For surgical procedures [χ2 (8) = 5.3, P = 0.73] and death [χ2 (8) = 3.78, P = 0.88], the tests showed solid correspondence between observed proportions and predicted probabilities. The AUC was 0.59 (95% CI: 0.55-0.62) for the outcome of rebleeding and 0.60 (95% CI: 0.54-0.67) for surgical procedures, representing apoor discriminative ability of the scoring system. For the outcome of death, the AUC was 0.73 (95% CI: 0.69-0.78), indicating an acceptable discriminative ability. CONCLUSION: The Rockall scoring system provides an acceptable tool to predict death, but performs poorly for endpoints of rebleeding and surgical procedures. | Robert A Enns Yves M Gagnon Alan N Barkun David Armstrong Jamie C Gregor Richard N Fedorak RUGBE Investigators Group | 2006 | World Journal of Gastroenterology2006，12，48： | 14 |
| 2 | Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study显示文摘AIM To identify demographic, clinical, metabolomic, and lifestyle related predictors of relapse in adult ulcerative colitis(UC) patients.METHODS In this prospective pilot study, UC patients in clinical remission were recruited and followed-up at 12 mo to assess a clinical relapse, or not. At baseline information on demographic and clinical parameters was collected. Serum and urine samples were collected for analysis of metabolomic assays using a combined direct infusion/liquid chromatography tandem mass spectrometry and nuclear magnetic resolution spectroscopy. Stool samples were also collected to measure fecal calprotectin(FCP). Dietary assessment was performed using a validated self-administered food frequency questionnaire. RESULTS Twenty patients were included(mean age: 42.7 ± 14.8 years, females: 55%). Seven patients(35%) experienced a clinical relapse during the follow-up period. While 6 patients(66.7%) with normal body weight developed a clinical relapse, 1 UC patient(9.1%) who was overweight/obese relapsed during the follow-up(P = 0.02). At baseline, poultry intake was significantly higher in patients who were still in remission during follow-up(0.9 oz vs 0.2 oz, P = 0.002). Five patients(71.4%) with FCP > 150 μg/g and 2 patients(15.4%) with normal FCP(≤ 150 μg/g) at baseline relapsed during the follow-up(P = 0.02). Interestingly, baseline urinary and serum metabolomic profiling of UC patients with or without clinical relapse within 12 mo showed a significant difference. The most important metabolites that were responsible for this discrimination were trans-aconitate, cystine and acetamide in urine, and 3-hydroxybutyrate, acetoacetate and acetone in serum. CONCLUSION A combination of baseline dietary intake, fecal calprotectin, and metabolomic factors are associated with risk of UC clinical relapse within 12 mo. | Ammar Hassanzadeh Keshtel iFloris F van den Brand Karen L Madsen Rupasri Mandal Rosica ValchevaKaren I Kroeker Beomsoo Han Rhonda C Bell Janis Cole Thomas Hoevers David S Wishart Richard N Fedorak Levinus A Dieleman | 2017 | World Journal of Gastroenterology2017，23，21： | 9 |
| 3 | Microscopic colitis:A large retrospective analysis from a health maintenance organization experience显示文摘AIM:To examine the demographic data on a large multi-ethnic population of patients with microscopic colitis (MC) in Southern California and to determine the association of MC with inflammatory bowel disease (IBD) and colorectal cancer.METHODS: All patients diagnosed with MC by colonic biopsy from 1996-2005 were identified utilizing a pathology database. All biopsies were reviewed by experienced pathologists utilizing standard histologic criteria. Patients' medical records were reviewed and data regarding patient age, co-morbidities, sex, ethnicity, and medications were analyzed. An age-and sexmatched standard control group was also generated. Chi-square test was used to evaluate the associations of co-morbidities between lymphocytic colitis (LC), collagenous colitis (CC) and the control group.RESULTS: A total of 547 cases of MC were identif ied,376 patients with LC and 171 patients with CC. The female/male ratio was 3:1 in CC and 2.7:1 in LC patients. Celiac disease (P<0.001), irritable bowel syndrome (IBS) (P<0.001), and thyroid diseases (P<0.001) were found to have a higher occurrence in MC compared to the control group. No statistical differences in the occurrence of colorectal cancer, diabetes and IBD were found between the MC group and the control group.CONCLUSION: This is the largest group of patients with MC known to the authors that has been studied to date. Conditions such as celiac disease, IBS, and thyroid diseases were found to be related to MC. Furthermore, neither an increased risk of colorectal cancer nor IBD was associated with MC in this study. | Kevin T Kao Benito A Pedraza Amy C McClune David A Rios Yi-Qiong Mao Robert H Zuch Michael H Kanter Sony Wirio Chris N Conteas | 2009 | World Journal of Gastroenterology2009，15，25： | 5 |
| 4 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 3 |
| 5 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 3 |
| 6 | Stem cell differentiation and human liver disease显示文摘Human stem cells are scalable cell populations capable of cellular differentiation.This makes them a very attractive in vitro cellular resource and in theory provides unlimited amounts of primary cells.Such an approach has the potential to improve our understanding of human biology and treating disease.In the future it may be possible to deploy novel stem cell-based approaches to treat human liver diseases.In recent years,eff icient hepatic differentiation from human stem cells has been achieved by several research groups including our own.In this review we provide an overview of the f ield and discuss the future potential and limitations of stem cell technology. | Wen-Li Zhou Claire N Medine Liang Zhu David C Hay | 2012 | World Journal of Gastroenterology2012，18，17： | 3 |
| 7 | Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial显示文摘 | Xin Shelley Wang Laurence D Rhines Almon S Shiu James N Yang Ugur Selek Ibrahima Gning Ping Liu Pamela K Allen Syed S Azeem Paul D Brown Hadley J Sharp David C Weksberg Charles S Cleeland Eric L Chang | 2012 | Lancet Oncology2012，，4： | 2 |
| 8 | 对应用选择性环氧酶2抑制剂或传统非甾体类抗炎药物老年患者上消化道出血的观察研究显示文摘目的 对应用选择性环氧酶2(COX 2)抑制剂和非选择性的非甾体类抗炎药(NSAIDs)的老年患者上消化道出血的比率进行比较。 设计 观察性队列研究。 设置 利用来自加拿大安大略2000年4月17日~2001年3月31日的官方数据,以确认基于人群的、初次使用NSAID的队列患者。 对象 年龄≥66岁,开始服用非选择性NSAIDs(n=5391)、双氯芬酸(diclofenac)加米索前列醇(misoprostol)(n=5087)、罗非昔布(rofecoxib)(n=14 583)或塞来昔布(celecoxib)(n=18 908),以及随机选择的没有服用NSAIDs的对照组(n=100 000)。 衡量结局的主要指标 每个药物组因上消化道出血入院的比值比(经过调整潜在的混杂因子)。 结果 与对照组相比,多变量模型表明,在服用非选择性NSAIDs(调整比值比为4.0,95%,可信区间为2.3~6.9,)、双氯芬酸加米索前列醇(3.0,1.7~5.6)以及罗非昔布(1.9,1.3~2.8)时,上消化道出血的短期危险性是增加的,而塞来昔布并没有增加(1.0,0.7~1.6)。与塞来昔布相比,非选择性的NSAIDs(4.4,2.3~8.5)、双氯芬酸加 米索前列醇(3.2,1.6—6.5)以及罗非昔布(1.9,1.2~2.8)的上消化道出血危险性显著增加。与罗非昔布相比,非选择性NSAIDs的上消化道出血危险性显著增加(1.9,1.0~3.5)。 结论 选择性COX | Muhammad Mamdani Paula A Rochon David N Juurlink Alex Kopp Geoffrey M Anderson Gary Naglie Peter C Austin Andreas Laupacis 邓瑞雪 | 2003 | 英国医学杂志中文版2003，6，3： | 2 |
| 9 | Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation显示文摘 | Alexandre Calon Elisa Espinet Sergio Palomo-Ponce Daniele V.F. Tauriello Mar Iglesias María Virtudes Céspedes Marta Sevillano Cristina Nadal Peter Jung Xiang H.-F. Zhang Daniel Byrom Antoni Riera David Rossell Ramón Mangues Joan Massagué Elena Sancho Edua | 2012 | Cancer Cell2012，，5： | 2 |
| 10 | Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of cellular fusion显示文摘 | Philip N Newsome Ingolfur Johannessen Shelagh Boyle Evangelos Dalakas Karen A Mcaulay Kay Samuel Frances Rae Lesley Forrester Marc L Turner Peter C Hayes David J Harrison Wendy A Bickmore John N Plevris | 2003 | Gastroenterology2003，，7： | 2 |
| 11 | Adipocyte iron regulates adiponectin and insulin sensitivity显示文摘 | Gabrielsen J Scott Gao Yan Simcox Judith A Huang Jingyu Thorup David Jones Deborah Cooksey Robert C Gabrielsen David Adams Ted D Hunt Steven C Hopkins Paul N Cefalu William T McClain Donald A | 2012 | EN2012，，10： | 2 |
| 12 | Simultaneous measurement of phytoplanktonic primary production,nutrient and light availability along a turbid,eutrophic UK east coast estuary(the Colne Estuary)显示文摘 | ESRA K GRAHAM J C U DAVID B N | 2002 | Marine Ecology Progress Series2002，231，： | 1 |
| 13 | LIGHT, a New Member of the TNF Superfamily, and Lymphotoxin α Are Ligands for Herpesvirus Entry Mediator显示文摘 | Davide N Mauri Reinhard Ebner Rebecca I Montgomery Kristine D Kochel Timothy C Cheung Guo-Liang Yu Steve Ruben Marianne Murphy Roselyn J Eisenberg Gary H Cohen Patricia G Spear Carl F Ware | 1998 | Immunity1998，，： | 1 |
| 14 | Bayesian Network Model for Reliability Assessment of Power Systems 显示文摘 | DAVID C Y THANH C N HADDAWAY P | 1999 | IEEE Transactions on Power Systems1999，14，2： | 1 |
| 15 | Host plant evaluation behaviour of Bemisia tabaci and its modification by external uptake of imidacloprid显示文摘 | RUFUS I MATTHEW C DAVID N B | 1999 | Physiol Entomol1999，24，： | 1 |
| 16 | High-Dose Split-Course Radiation Therapy for Anal Cancer: Outcome Analysis Regarding the Boost Strategy (CORS-03 Study)显示文摘 | Jean-Michel Hannoun-Levi Cécile Ortholan Michel Resbeut Eric Teissier Philippe Ronchin Didier Cowen Audrey Zaccariotto Karen Bénézery Eric Fran?ois Naji Salem Steve Ellis David Azria Jean-Pierre Gerard | 2011 | International Journal of Radiation Oncology Biology Physics2011，，3： | 1 |
| 17 | Bayesian network model for reliability assessment of power systems 显示文摘 | David C Y Thanh C N Peter H | 1999 | IEEE Trans on Power Systems1999，14，2： | 1 |
| 18 | Creep properties andprecipitate evolution in A1-Li alloys microalloyed with Sc and Yb显示文摘 | Matthew E K David N S David C D | 2012 | Materials Science and Engineering A2012，550，： | 1 |
| 19 | Linear multiuser receivers:effective interference effective bandwidth and user capacity 显示文摘 | Stephen V Hanly | 1999 | IEEE Transactions on information the ory1999，45，2： | 1 |
| 20 | Adeptive resource provisioning for read intensive multi-tier applications in the cloud显示文摘 | Waheed I Matthew N D David C | 2011 | Future Generation Computer Systems2011，27，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员